Fed Circuit refuses Amgen unit appeal in win for Sanofi
15-10-2020
MSD petitions SCOTUS over $2.5bn patent verdict
28-09-2020
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25-09-2017
Pavel Kapysh / Shutterstock.com
Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Idenix, genus patent, Gilead Sciences, Merck, hepatitis C, enablement requirement, Amgen, amicus brief, patent infringement
